Survival Outcomes of Breast-Conserving Therapy versus Mastectomy in Early-Stage Breast Cancer, Including Centrally Located Breast Cancer: A SEER-Based Study
Table 5
Multivariate logistic regression analysis of factors associated with BCT among CLBC patients.
OR
95% CI
-value
Age, years
0.001
64–72 vs. 18–63
1.186
1.082–1.300
< 0.001
73–79 vs. 18–63
1.037
0.925–1.162
0.538
Race
< 0.001
Black vs. white
1.088
0.948–1.248
0.229
Others vs. white
0.663
0.584–0.752
< 0.001
Histological type
IDC vs. ILC
1.361
1.187–1.560
< 0.001
Grade
< 0.001
I vs. III/IV
1.520
1.352–1.710
< 0.001
II vs. III/IV
1.193
1088-1.308
< 0.001
T stage
< 0.001
T1a vs. T2
2.884
2.479–3.354
< 0.001
T1b vs. T2
3.448
3.063–3.880
< 0.001
T1c vs. T2
2.271
2.075–2.486
<0.001
N stage
<0.001
N0 vs. N3
1.628
1.197–2.215
0.002
N1 vs. N3
1.203
0.882–1.640
0.243
N2 vs. N3
1.103
0.771–1.578
0.592
ER
Negative vs. positive
0,881
0,765–1.014
0.078
PR
Negative vs. positive
0.807
0.737–0.883
<0.001
Chemotherapy
No or unknown vs. yes
0.692
0.632–0.758
<0.001
CLBC, centrally located breast cancer; BCT, breast-conserving therapy; OR, odds ratio; CI, confidence interval; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor.
